Compare DexCom, Inc. (DXCM) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Royal Caribbean Cruises Ltd — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Royal Caribbean Cruises Ltd trades at $282.26 (market cap $75.26B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 2.4× DexCom, Inc.'s market cap, and Royal Caribbean Cruises Ltd pays a 2.13% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Royal Caribbean Cruises Ltd for 85 Days on average.
| DXCM | RCL | |
|---|---|---|
Market Cap | $31.86B | $75.26B |
Volume | 3,607,070 | 1,958,628 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $348.03 |
52-Week Low | $54.84 | $230.30 |
Typical Hold Time | 62 Days | 85 Days |
Enterprise Value | $31.32B | $97.91B |
Dividend Yield | — | 2.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
Royal Caribbean (RCL) trades at $281.39, down 0.35% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamental performance with 2025 revenue of $17.93B and net income of $4.27B, representing a 23.54% margin. Recent Q2 2026 earnings beat expectations at $4.21 EPS versus $3.98 expected, while the company expands into resorts through a $3B Sandals stake acquisition announced September 2026.
RCL presents a compelling growth story with improving profitability and strategic expansion, though elevated valuation multiples and high debt levels warrant caution. Analyst consensus remains bullish with a $346.67 price target representing 23% upside potential, but investors should monitor execution risks from the Sandals integration and sensitivity to fuel costs projected at $1.34B for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
